Charles Fain Lehman warned that President Donald Trump's order to have the Justice Department reschedule marijuana from Schedule I to Schedule III will chiefly benefit large cannabis companies, following Trump's move to direct federal officials to loosen marijuana restrictions.Lehman argued rescheduling would mainly deliver tax breaks by removing Internal Revenue Code section 280E limits and could expand harmful use despite claims it will ease research and reduce incarceration, citing CDC addiction estimates, a Journal of the American Medical Association review, and Congressional Research Service findings that a 2022 law had already eased some research barriers.